Navigation Links
Islet Sciences Announces Receipt of $2.1 Million in Grant Support of Technology
Date:4/9/2012

NEW YORK, April 9, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, announced today that its wholly-owned subsidiary DiaKine Therapeutics, Inc. has received grant support totaling approximately $2.1 million. The grants include $1,831,250 from the National Institutes of Health (NIH) and $250,000 from the Iacocca Foundation.

"Clearly, the receipt of these grants will help our company execute our ongoing initiatives and is a vote of confidence from such well known organizations," said Dr. Jerry L. Nadler, Islet Sciences Director. "As we continue to make progress with our diabetes therapies this grant support is a testament to the value of our therapies which represents such a large market opportunity for Islet Sciences."

"We are pleased to announce these grants which obviously strengthens our value proposition," said John Steel, Chairman and CEO of Islet Sciences. "Our approach to the treatment of diabetes in addition to other inflammatory diseases and autoimmune disorders are what attracted these esteemed institutions as we capitalize on the growing opportunities in this field. We look forward to announcing additional milestones in the coming months."

About Islet Sciences, Inc.

Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes.  The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties.   Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors.  Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission.  The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.

Investor Contact:
Jeff Ramson
ProActive Capital Resources Group
(646) 863 6893
jramson@proactivecrg.com

 


'/>"/>
SOURCE Islet Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
2. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
3. Beta-Pro Donates Human Islet Cells to Diabetes Researcher
4. Pigs to Be Genotyped to Improve Selection and Breeding for Pancreatic Islet Cell Research
5. BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes
6. Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration
7. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
8. Frost & Sullivan Announces Cutting Edge Life Sciences Research on the Horizon
9. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
10. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
11. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
(Date:10/9/2017)... ... 2017 , ... The award-winning American Farmer television series will feature 3 Bar ... Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ten billion ... continue to feed a growing nation. At the same time, many of our valuable ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first ... accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
Breaking Biology News(10 mins):